What is Vanda Pharmaceuticals's market cap?

Vanda Pharmaceuticals (VNDA) has a market capitalization of $313.9M and trades on NASDAQ.

Who are Vanda Pharmaceuticals's competitors?

Vanda Pharmaceuticals's key competitors include Johnson & Johnson, Scienture Holdings, Inc. Common Stock, Axsome Therapeutics, Inc, and others. These companies compete in similar markets and product categories.

Who does Vanda Pharmaceuticals partner with?

Vanda Pharmaceuticals's notable partners include Novartis Pharma AG, Bristol-Myers Squibb, Eli Lilly and Company, and others.

Where is Vanda Pharmaceuticals headquartered?

Vanda Pharmaceuticals is headquartered in United States of America and employs approximately 203 people. It has been publicly traded since 2006.

Vanda Pharmaceuticals

VNDA

Vanda Pharmaceuticals is a global biopharmaceutical company dedicated to developing and commercializing innovative therapies for high unmet medical needs.

Market cap

$313.91M+14.1%

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$51.7MMiss by $3.3M EPS-$0.82Miss by $0.29

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$61.9M

EPS estimate-$0.58

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Neurocrine Biosciences$17.7B+34.0%

Axsome Therapeutics$12.3B+148%

Opko Health$936.3M-12.5%

Rigel Pharmaceuticals$691.8M+93.6%

Puma Biotechnology$406.7M+145%

Vanda Pharmaceuticals$313.9M+13.3%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

By revenue growth

Axsome Therapeutics+63.9%

Rigel Pharmaceuticals+47.6%

Neurocrine Biosciences+28.6%

Johnson & Johnson+8.1%

Opko Health-11.5%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Neurocrine Biosciences21.55%+8.9pp

Johnson & Johnson21.48%-3.5pp

Opko Health-12.4%+14.3pp

Axsome Therapeutics-26.59%+37.8pp

Profile

Vanda Pharmaceuticals is a global biopharmaceutical company dedicated to developing and commercializing innovative therapies for high unmet medical needs. The company utilizes pharmacogenetics and pharmacogenomics expertise to differentiate its products and optimize clinical outcomes. Its core value proposition centers on bringing novel medicines to market for complex psychiatric, circadian, and inflammatory disorders.

Competitive position

Vanda is a specialized player in the orphan drug and psychiatric markets, holding first-to-market positions for specific circadian rhythm and developmental disorders.

GeographiesUnited States, Canada, European Union, Germany, Israel

Customer segmentsPatients with rare diseases, Psychiatric patients, Neurology patients, Specialty healthcare distributors

Business modelR&D-driven drug development, Product commercialization, IP licensing

SuppliersThird-party contract manufacturing organizations, Active pharmaceutical ingredient suppliers, Clinical research organizations, Academic research institutions

CustomersSpecialty pharmacies, Wholesale drug distributors, Hospitals, Government healthcare programs, Private insurance payors

CountryUnited States of America

Listed2006

Employees203.0

CEOMihael H. Polymeropoulos

SectorHealthcare

IndustryBiotechnology

Websitevandapharma.com

FilingsSEC EDGAR

Questions, answered.

What is Vanda Pharmaceuticals's market cap?: Vanda Pharmaceuticals (VNDA) has a market capitalization of $313.9M and trades on NASDAQ.
Who are Vanda Pharmaceuticals's competitors?: Vanda Pharmaceuticals's key competitors include Johnson & Johnson, Scienture Holdings, Inc. Common Stock, Axsome Therapeutics, Inc, and others. These companies compete in similar markets and product categories.
Who does Vanda Pharmaceuticals partner with?: Vanda Pharmaceuticals's notable partners include Novartis Pharma AG, Bristol-Myers Squibb, Eli Lilly and Company, and others.
Where is Vanda Pharmaceuticals headquartered?: Vanda Pharmaceuticals is headquartered in United States of America and employs approximately 203 people. It has been publicly traded since 2006.